SLC5A2 and Hyperglycemia: Importantly, the pharmacological inhibition of SGLT2 reduces hyperglycemia and glomerular hyperfiltration by suppressing renal glucose reabsorption to increase the excretion of urinary glucose, thereby reducing the risk of progression to chronic kidney disease (CKD) (16–19).